Monday’s Midday Movers: Agios Pharma (AGIO), Arrowhead Research (ARWR), Novavax (NVAX), Heron Therapeutics (HRTX), Pacira Pharmaceuticals (PCRX)

By Carrie Williams

So far Monday, September 30, NASDAQ is up 2.04% and the S&P is up 1.39%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Agios Pharma (AGIOResearch Report), Arrowhead Research (ARWRResearch Report), Novavax (NVAXResearch Report), Heron Therapeutics (HRTXResearch Report) and Pacira Pharmaceuticals (PCRXResearch Report).

Agios Pharma is down -8.79% in midday trading to $31.66. Shares opened today at $34.71. The company has a 52-week low of $31.46 and a 52-week high of $79.17. On the Street’s front, the average 12-month analyst price target for the stock is $67.25, marking a 93.75% potential upside from current levels. In a report issued on September 24, Piper Jaffray analyst Tyler Van Buren reiterated a Buy rating on AGIO, with a price target of $80.00, which represents a potential upside of 130% from where the stock is currently trading.

Arrowhead Research is up 8.11% in midday trading to $28.12. Shares opened today at $26.01. The company has a 52-week low of $10.41 and a 52-week high of $36.80. On the Street’s front, the average 12-month analyst price target for the stock is $42.67, marking a 64.05% potential upside from current levels. In a report issued on September 17, B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on ARWR, with a price target of $46.00, which implies an upside of 77% from current levels. In the last 30 days, insiders have sold $9.22M worth of ARWR shares. Over the last 3 months, the insider sentiment on Arrowhead Research has been negative based on 44 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Novavax is down -7.31% in midday trading to $5.22. Shares opened today at $5.63. The company has a 52-week low of $4.01 and a 52-week high of $51.60. On the Street’s front, the average 12-month analyst price target for the stock is $26.88, marking a 377.44% potential upside from current levels. In a report issued on September 24, B.Riley FBR analyst George Zavoico maintained a Buy rating on NVAX, with a price target of $35.00, which represents a potential upside of 522% from where the stock is currently trading. In the last 30 days, insiders have sold $117.1K worth of NVAX shares and purchased $32.4K worth of NVAX shares. Over the last 3 months, the insider sentiment on Novavax has been negative based on 9 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Heron Therapeutics is down -5.17% in midday trading to $18.72. Shares opened today at $19.74. The company has a 52-week low of $15.68 and a 52-week high of $32.45. On the Street’s front, the average 12-month analyst price target for the stock is $46.67, marking a 136.42% potential upside from current levels. In a report issued on August 18, Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on HRTX, with a price target of $38.00, which represents a potential upside of 93% from where the stock is currently trading.

See today’s analyst top recommended stocks >>

Pacira Pharmaceuticals is down -4.43% in midday trading to $38.16. Shares opened today at $39.93. The company has a 52-week low of $34.64 and a 52-week high of $55.00. On the Street’s front, the average 12-month analyst price target for the stock is $54.20, marking a 35.74% potential upside from current levels. In a report issued on September 17, Wedbush analyst Liana Moussatos reiterated a Buy rating on PCRX, with a price target of $85.00, which implies an upside of 113% from current levels. Separately, on August 9, BMO’s Gary Nachman maintained a Hold rating on the stock and has a price target of $43.00. In the last 30 days, insiders purchased $47.76K worth of PCRX shares. Over the last 3 months, the insider sentiment on Pacira Pharmaceuticals has been positive based on 44 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Trending Stocks Based on Insider Activity >>